Specializes in both open and closed prostate surgeries – Dr. Temel offers comprehensive treatment options at Büyük Anadolu Hospitals.
Trained in urological oncology at Memorial Sloan-Kettering Cancer Center – one of the world's leading cancer hospitals. Now heads the urology unit at Quirónsalud Marbella.
Dr. Lee Chunyong is a urologist with a PhD in Medicine from Hanyang University College of Medicine. His clinical focus includes kidney and urinary stones (ESWL), prostate diseases (BPH, prostate cancer, prostatitis), sexual dysfunction, vasectomy, cystitis, urinary incontinence, and voiding dysfunction.
He has served as Director of Hanyang University Hospital. He was Chairman and Chief Professor of the Department of Urology at Hanyang University College of Medicine. He served as President and later Honorary President of the Korean Endourological Society. He was also a Board Member of the Société Internationale d'Urologie.
His international roles include Visiting Fellow at UCLA and Visiting Professor at the University of Tübingen. He was featured twice on EBS “Best Doctors,” covering prostatic diseases and kidney and urinary stones.
Bruce Patrik Dos Santos Marcano brings a unique blend of technical precision and aesthetic vision to plastic surgery at Quiron Barcelona.
Specializing in medical oncology since 2018, Dr. Alemdar focuses on prostate cancer treatment at Medical Park Antalya Hospital Complex.
Associate Professor Ozkan Onuk specializes in urology with a focus on prostate cancer treatments at Medical Park Bahcelievler Hospital.
Dr. George Tie specializes in minimally invasive prostate surgery, including TURP and laser procedures, ensuring precision and patient comfort.
Dr. Kurshad Zengin brings over 22 years of urology experience, specializing in prostate procedures at Lokman Hekim Akay Hospital.
Dr. Hasan Anıl Atalay is a urologist focused on uro‑oncology, reconstructive urology, and stone disease. He has expertise in laparoscopic and robotic surgery. He trained at Cerrahpaşa Faculty of Medicine and Istanbul Training & Research Hospital. He completed advanced training at Memorial Sloan Kettering Cancer Center (2010–2011) and World Laparoscopy Hospital (2019–2020).
He has authored more than 30 peer‑reviewed papers (2016–2021). Topics include CT texture to predict ESWL outcomes, VI‑RADS in bladder cancer, renal function after partial nephrectomy, PCNL fluoroscopy and stone metrics, sexual dysfunction, urosepsis biomarkers, and 3D models for PCNL and patient education. He is a member of the European Urology Association, the Turkish Urology Association, and the Urological Surgery Association.
Prof. Yurdakul specializes in uro-oncology with fellowship training at Cleveland Clinic – a leader in prostate cancer treatment.
Urologist, Surgeon
Dr. Vladimir Yutkin brings over 30 years of expertise to prostatectomy at Hadassah Medical Center.
Professor Kim Hyun-hoe is a urologic cancer surgeon. He specializes in prostate and kidney cancer and robotic surgery. He directs Myongji Hospital’s Robotic Surgery Center and the Prostate & Kidney Cancer Center. He performed Korea’s first single-incision laparoscopy. At SNUH, he led more than 2,300 da Vinci cases over five years. He now uses the da Vinci Xi system.
He holds an MD, MS, and PhD from Seoul National University. He is a former director of SNUH Robotic Surgery and the Urology/Prostate Cancer Center. He is a past president of the Korean Society of Endourology and Robotics. He is a council member of the Korean Urological Association. His awards include the WCE Best Laparoscopy/Robotic Paper and the KUA Best Paper. He has also received several national academic honors. He contributes to next‑generation da Vinci research with Seoul National University and Intuitive Surgical. This was the first such collaboration in Asia.
The doctor is a highly experienced urology specialist serving as the Head of the Urology Department at Hospital Quirónsalud Torrevieja since 2017. With a medical degree and specialization from Johannes Gutenberg University in Germany, the doctor has extensive clinical experience dating back to 2007. The doctor's expertise encompasses oncological urology, prostate diseases, and complex urinary tract conditions.
A key focus of the doctor's practice is robotic urological surgery, specifically utilizing the Da Vinci surgical system for prostate cancer procedures. The doctor has contributed to academic literature, including chapters in Differentialdiagnose Urologie, and maintains a strong focus on providing high-quality care for both local and international patients.
Dr. Jang Hyun Kyung is a board-certified urologist. She completed her residency and clinical fellowship at Gachon University Gil Medical Center. She later served as a Clinical Assistant Professor of Urology at Korea University Ansan Hospital and at International St. Mary’s Hospital.
Her clinical interests include BPH, urolithiasis, urinary incontinence and voiding dysfunction, and urinary tract infections. She also focuses on male urology, pediatric urology, and urologic ultrasound.
Professional memberships: Full member of the Korean Urological Association, the Korean Continence Society, the Korean Society of Pediatric Urology, the Korean Association of Urogenital Tract Infection and Inflammation, and the Korean Society of Urological Ultrasound. Current affiliation: Urologist, Gibbeum Hospital.
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Associate Professor Cem Basatac specializes in laparoscopic prostatectomy at Gayrettepe Florence Nightingale Hospital.
Dr. Dorit Zilberman is a senior urologist at Sheba Medical Center in Israel. She is a pioneer of robotic and minimally invasive urologic surgery. Dr. Zilberman treats kidney, bladder, and prostate cancers. She helped launch the da Vinci robotic surgery program at Sheba. Forbes Israel recognized her among the nation's best doctors.
Dr. Nir Kleinmann directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is a pioneer in kidney-sparing laser surgery for complex tumors. Forbes and ResultMed named him among Israel’s Best Doctors for 2025 and 2026. Dr. Kleinmann uses a unique dual-laser system to preserve organ function during cancer treatment.
Over 50 scientific publications and leadership at Israel's top cancer center — Dr. Zohar Dotan is among Israel’s few fellowship-trained uro-oncologists.